COCP Cocrystal Pharma Inc

Cocrystal Pharma to Present at the LD Micro Main Event XV

Cocrystal Pharma to Present at the LD Micro Main Event XV

BOTHELL, Wash., Oct. 19, 2022 (GLOBE NEWSWIRE) -- (Nasdaq: COCP) announces that President and co-interim CEO Sam Lee, PhD will present a company overview of their antiviral programs and clinical trials at the LD Micro Main Event XV on Wednesday, October 26 at 3:30 p.m. Pacific time (6:30 p.m. Eastern time). The conference is being held at the Luxe Sunset Boulevard Hotel in Los Angeles.

A webcast of the presentation will be available live and archived on the of the company website.

About Cocrystal Pharma, Inc.

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), hepatitis C viruses and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit .

Investor Contact:

LHA Investor Relations

Jody Cain

310-691-7100

Media Contact:

JQA Partners

Jules Abraham

917-885-7378

# # #



EN
19/10/2022

Underlying

COCPCocrystal Pharma Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cocrystal Pharma Inc

 PRESS RELEASE
Free
COCP Cocrystal Pharm...

Cocrystal Pharma, Inc. Announces Closing of Up To $13 Million Register...

Cocrystal Pharma, Inc. Announces Closing of Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules $4.7 million upfront with up to an additional approximately $8.3 million of potential aggregate gross proceeds upon the exercise in full of warrants BOTHELL, Wash., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc., (Nasdaq: COCP) (the “Company” or “Cocrystal”), today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 2,764,710 shares of its common stock at a ...

September 15, 2025 1 EN
 PRESS RELEASE
Free
COCP Cocrystal Pharm...

Cocrystal Pharma, Inc. Announces Up To $13 Million Registered Direct O...

Cocrystal Pharma, Inc. Announces Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules $4.7 million upfront with up to an additional approximately $8.3 million of potential aggregate gross proceeds upon the exercise in full of warrants BOTHELL, Wash., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc., (Nasdaq: COCP) (the “Company” or “Cocrystal”), today announced that it has entered into definitive agreements for the purchase and sale of 2,764,710 shares of its common stock (or common stock equivalents in lieu thereof) at a purchase price of $1.70 p...

September 12, 2025 1 EN
 PRESS RELEASE
Free
COCP Cocrystal Pharm...

Cocrystal Pharma Showcases CDI-988, the First Oral Antiviral in Develo...

Cocrystal Pharma Showcases CDI-988, the First Oral Antiviral in Development for Norovirus Infection, in a Podium Presentation at the International Calicivirus Conference BOTHELL, Wash., Sept. 12, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: COCP) announces that President and co-CEO Sam Lee, PhD discussed the scientific foundation and clinical progress with the Company’s lead pan-viral protease inhibitor CDI-988 during a podium presentation at the 9th , held September 7–11, 2025 in Banff, Alberta. Based on a novel mechanism of action and superior broad-spectrum antiviral activity, CDI-988 represent...

September 12, 2025 1 EN
 PRESS RELEASE
Free
COCP Cocrystal Pharm...

Cocrystal Pharma Receives FDA IND Clearance for Challenge Study of Ora...

Cocrystal Pharma Receives FDA IND Clearance for Challenge Study of Oral Broad-Spectrum Protease Inhibitor CDI-988, a Potential First Antiviral for Norovirus Prevention and Treatment There are currently no approved vaccines or treatments for norovirus infectionCocrystal’s CDI-988 is the first antiviral for the potential prevention and treatment of viral gastroenteritis caused by norovirus infections Phase 1b study is expected to start by year-end 2025 BOTHELL, Wash., Sept. 08, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that the Company received a Stu...

September 8, 2025 1 EN
 PRESS RELEASE
Free
COCP Cocrystal Pharm...

Cocrystal Pharma to Participate at the H.C. Wainwright Global Investme...

Cocrystal Pharma to Participate at the H.C. Wainwright Global Investment Conference BOTHELL, Wash., Sept. 03, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that James Martin, CFO and co-CEO, will present a company overview at the H.C. Wainwright 27th Annual Global Investment Conference on Tuesday, September 9, 2025 at 12:00 p.m. Eastern time. Mr. Martin will be available throughout the conference for in-person and virtual one-on-one meetings. Institutional investors and industry professionals can to attend the conference virtually or in-person at the...

September 3, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch